We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. The company's products portfolio includes respiratory products, such as Karvol Plus, Febrex Plus, Dropizin, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform Toothpaste, Sensoform Gum Paint, Rexidin M, Rexidin SRS, RR Sensoform Dental, Sensodent-KF, Poviclean, Rexidin, Sensodent-R, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastrointestinal products, such as Carmicide, Cyclopam, Cyclopam Plus, Cyclomeff, and Nosic; pain/analgesics products that include Lignox A and Lignox ; and ophthal/otologicals products, such as Renolen, Homide, Dexoren S, Zincoren, Bfloren, Dexoren, Otorex, Mofloren-D, Mofloren BF, Macuchek, and Mofloren LP. It also provides vitamins/minerals/nutrients that include Methycal, Cital UTI, SM Fibro, Coloferrin, Cal Aid, and MCBM DHA; urology products, such as Cital-H and Cital; Cloben G, Noxa, and Scabex for dermatology; ATM, Clygan, Vepan, and Oxipod for anti-infectives; Hemsyl for blood related therapies; MCBM 69 and D-Chiro for gynecological; Aloja and Aloja M for Anti-Diabetics; and Spear for anti-haemorrhoidal. In addition, the company provides analytical services, such as impurity profile, particle size analysis, heavy metal analysis, polymorphism and compatibility studies, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, it offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.
TODAY'S HIGH
401
TODAY'S LOW
384.2
52 WEEK HIGH
459.25
52 WEEK LOW
307.65
% of Shares Held by
All Insider
60.07%
% of Shares Held by
Institutions
18.44%
% of Float Held by
Institutions
46.17%
Number of Institutions
Holding Shares
21
MARKET CAP
3664.36 Cr.
ETERPRISE VALUE
3802.32 Cr.
NO. OF SHARES
9.21 Cr.
BOOK VALUE
105.357
DIV. YIELD
0.75%
DEBT
298.59 Cr.
GROSS PROFIT
1044.81 Cr.
CASH
41.38 Cr.
REVENUE
1608.39 Cr.
REVENUE/SHARE
174.5
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 0 | 0 | 0 | -11.12 Lakhs |
| Change To Liabilities | 21.43 Cr. | -50.70 Cr. | -5.04 Cr. | 22.27 Cr. |
| Total cashflows from Investing Activities | -121.41 Cr. | -66.69 Cr. | -55.93 Cr. | -103.75 Cr. |
| Net Borrowings | -15.59 Cr. | -3.88 Cr. | -38.25 Cr. | 15.76 Cr. |
| Total Cash from Financing Activities | -44.37 Cr. | -29.87 Cr. | -63.94 Cr. | -16.14 Cr. |
| Other Liabilities | 1.21 Cr. | -19.29 Cr. | 46.26 Cr. | 9.14 Cr. |
| Total Assets | 0 | 0 | 0 | 0 |
| Net Income | 154.80 Cr. | 93.04 Cr. | 24.11 Cr. | -2.90 Cr. |
| Change in Cash | 8.05 Cr. | -14.34 Cr. | 2.96 Cr. | 12.21 Cr. |
| Effect of Exchange Rate | 0 | 0 | 0 | 0 |
| Total Cash from Operating Activities | 173.83 Cr. | 82.22 Cr. | 122.84 Cr. | 132.11 Cr. |
| Depreciation | 78.96 Cr. | 49.78 Cr. | 47.75 Cr. | 41.89 Cr. |
| Other Cashflows from Investing Activities | 2.97 Cr. | 9.95 Cr. | 2.43 Cr. | -10.64 Cr. |
| Dividends Paid | -13.79 Cr. | -2.78 Cr. | -3.36 Cr. | -11.09 Cr. |
| Change to Inventory | -72.66 Cr. | -29.53 Cr. | -24.86 Cr. | 9.93 Cr. |
| Change to Account Receivables | -58.78 Cr. | -40.27 Cr. | -17.84 Cr. | 14.26 Cr. |
| Other Cashflows from Financing Activities | -14.99 Cr. | -23.20 Cr. | -22.33 Cr. | -20.81 Cr. |
| Change to Net Income | 48.87 Cr. | 55.86 Cr. | 32.26 Cr. | 7.83 Cr. |
| Capital Expenditures | -125.32 Cr. | -76.84 Cr. | -58.46 Cr. | -96.94 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | 74.64 Cr. | 59.70 Cr. | 49.70 Cr. | 51.51 Cr. |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 236.57 Cr. | 131.99 Cr. | 28.57 Cr. | -9.31 Cr. |
| Minority Interest | None | None | None | None |
| Net Income | 250.71 Cr. | 153.08 Cr. | 55.59 Cr. | 6.68 Cr. |
| Selling General Administrative | 293.70 Cr. | 317.57 Cr. | 308.65 Cr. | 271.58 Cr. |
| Gross Profit | 1086.29 Cr. | 857.35 Cr. | 746.64 Cr. | 621.44 Cr. |
| Ebit | 250.71 Cr. | 153.08 Cr. | 55.59 Cr. | 6.68 Cr. |
| Operating Income | 250.71 Cr. | 153.08 Cr. | 55.59 Cr. | 6.68 Cr. |
| Other Operating Expenses | 388.28 Cr. | 237.34 Cr. | 256.73 Cr. | 219.58 Cr. |
| Interest Expense | -14.14 Cr. | -21.04 Cr. | -22.30 Cr. | -19.96 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 81.77 Cr. | 38.95 Cr. | 4.45 Cr. | -6.40 Cr. |
| Total Revenue | 1543.08 Cr. | 1241.52 Cr. | 1106.58 Cr. | 968.44 Cr. |
| Total Operating Expenses | 1292.37 Cr. | 1088.44 Cr. | 1050.99 Cr. | 961.76 Cr. |
| Cost of Revenue | 456.79 Cr. | 384.17 Cr. | 359.93 Cr. | 347 Cr. |
| Total Other Income Expense Net | -14.14 Cr. | -21.08 Cr. | -27.01 Cr. | -15.99 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 154.80 Cr. | 93.04 Cr. | 24.11 Cr. | -2.90 Cr. |
| Net Income Applicable to Common Shares | 154.80 Cr. | 93.04 Cr. | 24.11 Cr. | -2.90 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 91.88 Cr. | 84.51 Cr. | 91.40 Cr. | 95.14 Cr. |
| Capital Surplus | 0 | 64.20 Cr. | 64.20 Cr. | 64.20 Cr. |
| Total Liabilities | 581.45 Cr. | 546.07 Cr. | 592.02 Cr. | 597.42 Cr. |
| Stock Holder Equity | 904.64 Cr. | 768.99 Cr. | 679.56 Cr. | 660.62 Cr. |
| Minority Interest | 0 | 0 | 0 | 0 |
| Other Liabilities | 141.75 Cr. | 104.30 Cr. | 98.64 Cr. | 79.83 Cr. |
| Total Assets | 1486.09 Cr. | 1315.06 Cr. | 1271.59 Cr. | 1258.04 Cr. |
| Common Stock | 18.43 Cr. | 18.43 Cr. | 18.43 Cr. | 18.43 Cr. |
| Retained Earnings | 0 | 686.35 Cr. | 596.92 Cr. | 577.98 Cr. |
| Other Liabilities | 49.75 Cr. | 35.20 Cr. | 30.61 Cr. | 23.26 Cr. |
| Good Will | 9 Lakhs | 9 Lakhs | 9 Lakhs | 9 Lakhs |
| Treasury Stock | 886.21 Cr. | 2 k | 2 k | 2 k |
| Other Assets | 35.82 Cr. | 54.38 Cr. | 68.02 Cr. | 66.89 Cr. |
| Cash | 19.78 Cr. | 9.41 Cr. | 23.76 Cr. | 20.79 Cr. |
| Current Liabilities | 424.86 Cr. | 406.91 Cr. | 458.98 Cr. | 445.50 Cr. |
| Long Term Asset Charges | 0 | 19.35 Cr. | 35.90 Cr. | 35.50 Cr. |
| Short Long Term Debt | 0 | 44.94 Cr. | 58.80 Cr. | 54.25 Cr. |
| Other Stockholder Equity | 886.21 Cr. | 2 k | 2 k | 2 k |
| Property Plant Equipment | 584.66 Cr. | 553.53 Cr. | 548.94 Cr. | 557.84 Cr. |
| Total Cur. Assets | 773.62 Cr. | 622.52 Cr. | 563.10 Cr. | 538.05 Cr. |
| Long Term Investments | 2 Lakhs | 2.10 Lakhs | 2.10 Lakhs | 2.10 Lakhs |
| Net Tangible Assets | 812.67 Cr. | 684.38 Cr. | 588.07 Cr. | 565.38 Cr. |
| Short Term Investments | 0 | 0 | 0 | 0 |
| Net Receivables | 297.78 Cr. | 235.38 Cr. | 211.28 Cr. | 196.48 Cr. |
| Long Term Debt | 95.88 Cr. | 96.93 Cr. | 96.93 Cr. | 128.65 Cr. |
| Inventory | 310.52 Cr. | 237.85 Cr. | 208.31 Cr. | 183.45 Cr. |
| Accounts Payable | 133.29 Cr. | 113.22 Cr. | 165.60 Cr. | 170.72 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account